Company intelligence

Alzamend Neuro

BiotechActive

Is this your company? Get featured or correct your listing →

Suggest a correction

We're still building this profile — here is what Pulse has covered.

Latest Pulse

  1. Three Biotechs File S-1s in the Same WeekTempest Therapeutics, Aptevo Therapeutics and Alzamend Neuro all filed S-1 registration statements this week, a reminder that the biotech IPO pipeline keeps moving even in a news cycle dominated by trillion-dollar AI listings.→
  2. Where 2026's Record IPO Money Is Actually LandingBreak 2026's roughly $160B in IPO proceeds down by sector and it's concentrated in a handful of mega-deals -- space, AI and defense -- while smaller biotech, SPAC and fintech listings continue at a steadier pace underneath.→

Coverage Timeline

newest first
  1. Aug 21, 2026IPOThree Biotechs File S-1s in the Same Week→

All Coverage

IPO

Three Biotechs File S-1s in the Same Week

Illustration for: Three Biotechs File S-1s in the Same Week
IPO

Three Biotechs File S-1s in the Same Week

Tempest Therapeutics, Aptevo Therapeutics and Alzamend Neuro all filed S-1 registration statements this week, a reminder that the biotech IPO pipeline keeps moving even in a news cycle dominated by trillion-dollar AI listings.

DEEP DIVE

Related Companies

Same sector
Scribe TherapeuticsAttovia TherapeuticsIambic TherapeuticsApnimedRetension PharmaceuticalsEli Lilly